Your browser doesn't support javascript.
loading
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Nakamura, Ritsuko; Oyama, Takeru; Inokuchi, Masafumi; Ishikawa, Satoko; Hirata, Miki; Kawashima, Hiroko; Ikeda, Hiroko; Dobashi, Yoh; Ooi, Akishi.
Afiliação
  • Nakamura R; Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
  • Oyama T; Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
  • Inokuchi M; Department of Breast Oncology, Division of Cancer Medicine, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
  • Ishikawa S; Department of Breast and Endocrine Surgery, Kanazawa Medical University, Ishikawa, Japan.
  • Hirata M; Department of Breast Oncology, Division of Cancer Medicine, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
  • Kawashima H; Department of Breast Oncology, Division of Cancer Medicine, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
  • Ikeda H; Radiology Division, Kanazawa University Hospital, Ishikawa, Japan.
  • Dobashi Y; Diagnostic Pathology, Kanazawa University Hospital, Ishikawa, Japan.
  • Ooi A; Department of Pathology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Pathol Int ; 70(6): 330-339, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32103597
ABSTRACT
Most breast cancers are derived from the luminal epithelium, which composes the inside of the breast ductal structure. Ductal carcinoma in situ (DCIS) leads to invasive ductal carcinoma, but noncancerous intraductal proliferative lesions are also a risk factor for ductal carcinoma. The transforming growth factor beta (TGFB) signaling pathway behaves as a tumor suppressor in the early stage of cancer, and conversely as a tumor growth factor in invasive stages in several cancers. In this study, we performed immunohistochemistry with an antibody that detects the cytoplasmic region of TGFB receptor 1 (TGFBR1) and elucidated TGFBR1 protein expression in luminal epithelial cells of noncancerous breast ducts and in several cases of DCIS and invasive carcinoma. TGFBR1 expression was higher in noncancerous breast tissue than in cancerous tissue, and a difference in expression was also seen among histological subtypes. Comparing the expression level of TGFBR1 in cancer cells and clinico-pathological parameters, cases expressing low TGFBR1 tended to show low estrogen receptor expression, large tumor size (≥10 mm), and a high Ki67 labeling index. These data suggested that TGFBR1 protein expression may be related to the suppression of breast cancer cell growth.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Ductal de Mama / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Ductal de Mama / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article